DGAP-News: CureVac to Report Fourth Quarter and Full-Year 2020 Financial Results and Business Updates on April 15, 2021
Examples include discussion of the potential efficacy of the company's vaccine and treatment candidates and the company's strategies, financing plans, growth opportunities and market growth.
DGAP-News: CureVac / Key word(s): Miscellaneous CureVac to Report Fourth Quarter and Full-Year 2020 Financial Results and Business Updates on April 15, 2021 09.04.2021 / 13:20 The issuer is solely responsible for the content of this announcement. CureVac to Report Fourth Quarter and Full-Year 2020 Financial Results and Business Updates on April 15, 2021 TÜBINGEN, Germany/ BOSTON, USA - April 9, 2021 - CureVac N.V. (Nasdaq: CVAC), a biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid ("mRNA"), will report financial results and business updates for the fourth quarter and Full-Year of 2020 on Thursday, April 15, 2021. The company will host a conference call and webcast on the same day at 4:00 p.m. CET / 10:00 a.m. EST. Conference call and webcast details Dial-in numbers to participate in the conference call: The live webcast link can be accessed via the Investor Relations section of the CureVac homepage at https://www.curevac.com/en/newsroom/events/ CureVac Media Contact Forward-Looking Statements For further information, please reference the company's reports and documents filed with the U.S. Securities and Exchange Commission (SEC). You may get these documents by visiting EDGAR on the SEC website at www.sec.gov
09.04.2021 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG. |
Language: | English |
Company: | CureVac |
Friedrich-Miescher-Str. 15 | |
72076 Tübingen | |
Germany | |
EQS News ID: | 1183036 |
End of News | DGAP News Service |
|
1183036 09.04.2021